Intravenous immunoglobulin in autoimmune and inflammatory dermatoses. A review of proposed mechanisms of action and therapeutic applications.
Off-label use of intravenous immunoglobulin (IVIG) at high doses has resulted in numerous anecdotal reports of its effectiveness in a variety of autoimmune and inflammatory conditions. Despite its growing acceptance as a viable therapeutic option in the management of several such disorders, the poorly defined mechanism of action of IVIG has stifled its rational therapeutic application. The lack of carefully designed prospective randomized clinical trials has further fueled controversy and mitigates against optimal application of this burgeoning therapy. Nevertheless, some standardization of IVIG therapy is slowly advancing that promises to support the use of this treatment for a growing number of autoimmune and inflammatory dermatoses.
Colsky
A S
AS
Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Florida, USA.
D001327:Autoimmune Diseases / Q000188:drug therapy*; D003882:Dermatomyositis / Q000188:drug therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D010257:Paraneoplastic Syndromes / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy
D016756:Immunoglobulins, Intravenous